AD-218 is under clinical development by Addpharma and currently in Phase III for Mixed Dyslipidemia. According to GlobalData, Phase III drugs for Mixed Dyslipidemia have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how AD-218’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AD-218 is under development for the treatment of hyperlipidemia and mixed dyslipidemia. It is an incrementally modified drug (IMD). It is administered through oral route.
Addpharma is a specialized pharmaceutical company that develops medicinal novel drugs including complexes, release controlling agents, and absorption improving agents. Addpharma is headquartered in Yongin, South Korea.
For a complete picture of AD-218’s drug-specific PTSR and LoA scores, buy the report here.